inebilizumab
AssetAlso Uplizna, MEDI-551
Binds CD19 and depletes B cells, reducing pathogenic autoantibody production.
- Stage
- Approved
- Modality
- Antibody
- Target
- Inflammation
- 2
- Indications
- 1
- Trial
- 2
- Developers
Indications
2Generalized myasthenia gravis
Approved, answers.and-pro.jp, 12 Oct 2026
Membranous glomerulonephritis
Phase 3, Recruiting, NCT07851220, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners2
- Trials1
- Evidence for its targets3
- Competitors11
- Aging relevance1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.